Clozapine occupies high levels of dopamine D2 receptors

Life Sciences

Volumn 60, Issue 12, 1997, Pages PL207-PL216

  Seeman, Philip ^a   Kapur, Shitij ^a  

^a NONE

Author keywords

antipsychotic drug; caudate nucleus; neuroleptic; PET; schizophrenia

Indexed keywords

BUTACLAMOL; CLOZAPINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; RACLOPRIDE; RADIOLIGAND; SULPIRIDE;

ARTICLE; BINDING COMPETITION; BRAIN; CAUDATE NUCLEUS; HUMAN; PARTITION COEFFICIENT; PSYCHOSIS; RECEPTOR DENSITY; RECEPTOR OCCUPANCY;

EID: 0343907220     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0024-3205(97)00026-x     Document Type: Article

References (25)

1. P. SEEMAN, Neuropsychopharmacology 7 261-284 (1992).
2. C. NORDIN, B. ALMÉ, and U. BONDESSON, Psychopharmacology 122 104-107 (1995).
3. S. NYBERG, A.-L. NORDSTRÖM, C. HALLDIN and L. FARDE, Int. Clin. Psychopharmacol. 10 Suppl 3 81-85 (1995).
4. S. NYBERG, L. FARDE, C. HALLDIN, M.-L. DAHL and L. BERTILSSON, Am. J. Psychiatry 152 173-178 (1995).
5. L. FARDE, A.-L. NORDSTRÖM, F.-A. WIESEL, S. PAUL, C. HALLDIN and G. SEDVALL, Arch. Gen. Psychiatry 49 538-544 (1992).
6. S. KAPUR, G. REMINGTON, C. JONES, P. ROY, K. REED, S. HOULE and R.B. ZIPURSKY, Biol. Psychiatry 39 512-513 (1996).
7. A.-L. NORDSTRÖM, L. FARDE, S. NYBERG, P. KARLSSON, C. HALLDIN and G. SEDVALL, Am. J. Psychiatry 152 1444-1449 (1996).
8. A. WOLKIN, J.D. BRODIE, F. BAROUCHE, J. ROTROSEN, A.P. WOLF, M. SMITH, J. FOWLER and T.B. COOPER, Arch. Gen. Psychiatry 46 482-483 (1989).
9. J.W. LOUWERENS, J.A. BUDDINGH, S. ZIJLSTRA, J. PRUIM, J. KORF, A.M.J. PAANS, W. VAALBURG and C.J. SLOOF, New Generation of Antipsychotic Drugs: Novel Mechanisms of Action, N. Brunello, J. Mendlewicz, and G. Racagni, (Eds), Vol. 4, 130-135, Karger, Basel (1993).
10. R. CONLEY, M. ZHAO, D. WONG and C. TAMMINGA, Biol. Psychiatry 39 513 (1996).
11. H. KARBE, K. WIENHARD, K. HAMACHER, M. HUBER, K. HERHOLZ, H.H. COENEN, G. STÖCKLIN, A. LÖVENICH and W.D. HEISS, J. Neural Transm. 86 163-173 (1991).
12. P. SEEMAN and H.H.M. VAN TOL, Eur. J. Pharmacol. 291 59-66 (1995).
13. P. SEEMAN, Int. Clin. Psychopharmacol. 10 Suppl 3 5-13 (1995).
14. Y.-C. CHENG and W.H. PRUSOFF, Biochem. Pharmacol. 22 3099-3108 (1973).
15. P.J. MUNSON and D. RODBARD, J. Receptor Res. 8 533-546 (1988).
16. P. SEEMAN, R. CORBETT, D. NAM, and H.H.M. VAN TOL, Jpn. J. Pharmacol. 71 187-204 (1996).
17. P. SEEMAN, R. CORBETT, and H.H.M. VAN TOL, Neuropsychopharmacology (1997, in press).
18. P. SEEMAN, Pharmacol. Rev. 24 583-655 (1972).
19. P. SEEMAN, Pharmacol. Rev. 30 229-313 (1980).
20. T.-P. SU, A. BREIER, R. COPPOLA, K. HADD, I. ELMAN, C. ADLER, A.K. MALHOTRA, E. WATSKY, J. GOREY, D. WEINBERGER and D. PICKAR, Biol. Psychiatry 39 512-513 (1996).
21. M.B. KNABLE, A. HEINZ, R. COPPOLA, J. GOREY and D.R. WEINBERGER, Biol. Psychiatry 39 515 (1996).
22. M. KRAMER, D. ZIMBROFF, B. LAST, A. GETSON and the D4 Antagonist Study Group, New Clin. Drug Evaulation Unit Meeting, May 28-31, Abstr. 106 (1996).
23. D.F. WONG, H.N. WAGNER, Jr., L.E. TUNE, R.F. DANNALS, G.D. PEARLSON, J.M. LINKS, C.A. TAMMINGA, E.P. BROUSOLLE, H.T. RAVERT, A.A. WILSON, J.K.T. TOUNG, J. MALAT, J.A. WILLIAMS, L.A. O'TUAMA, S.H. SYNDER, M.H. KUHAR, and A. GJEDDE, Science 234 1558-1563 (1986).
24. H.H.M. VAN TOL, J.R. BUNZOW, H.-C. GUAN, R.K. SUNAHARA, P. SEEMAN, H.B. NIZNIK and O. CIVELLI, Nature 350 610-614 (1991).
25. R. MARKSTEIN, P. GULL, C. RÜDEBERG, S. URWYLER, A.L. JATON, H.O. KALKMAN, A.K. DIXON and D. HOYER, J. Neural Transm. 103 17-30 (1996).